Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disorder characterized by the pathologic accumulation of sphingomyelin (SM) in multiple cell types, and occurs most prominently within the liver, spleen, and lungs, leading to significant clinical disease. Seventeen ASMD patients underwent a liver biopsy during baseline screening for a phase 1 trial of recombinant human acid sphingomyelinase (rhASM) in adults with Niemann-Pick disease type B. Eleven of the 17 were enrolled in the trial and each received a single dose of rhASM and underwent a repeat liver biopsy on day 14. Biopsies were evaluated for fibrosis, SM accumulation, and macrophage infiltration by light and electron microscopy. When present, fibrosis was periportal and pericellular, predominantly surrounding affected Kupffer cells. Two baseline biopsies exhibited frank cirrhosis. SM was localized to isolated Kupffer cells in mildly affected biopsies and was present in both Kupffer cells and hepatocytes in more severely affected cases. Morphometric quantification of SM storage in liver biopsies ranged from 4% to 44% of the microscopic field. Skin biopsies were also performed at baseline and day 14 to compare the SM distribution in a peripheral tissue with that of liver. SM storage was present at lower levels in multiple cell types of the skin, including dermal fibroblasts, macrophages, vascular endothelial cells, vascular smooth muscle cells, and Schwann cells. This phase 1 trial of rhASM in adults with ASMD provided a unique opportunity for a prospective assessment of hepatic and skin pathology in this rare disease and their potential usage as pharmacodynamic biomarkers.
A cid sphingomyelinase deficiency (ASMD) is a lysosomal storage disorder that is also known as Niemann-Pick disease (NPD), which is of 2 types-type A (NPD-A) and type B (NPD-B)-corresponding to 2 ends of a clinical spectrum resulting from deficiency of the same enzyme activity. 9 NPD-A is an infantile-onset disease characterized by failure to thrive, hepatosplenomegaly, neurodegeneration, and death in early childhood. NPD-B has variable ages of onset, heterogeneous symptoms, little to no neurological involvement, and survival into adolescence and adulthood. 6, 21 Due to the deficiency of acid sphingomyelinase (ASM) enzyme activity, its substrate, sphingomyelin (SM), accumulates within lysosomes. Pathologic accumulation of SM occurs most prominently within the monocyte/macrophage cell lineage of the reticuloendothelial system, resulting in hepatosplenomegaly, interstitial lung disease, and bone marrow infiltration. 8, 19 This cellular accumulation begins in utero, as demonstrated by the 4-fold and 2.5-fold increases in hepatic and splenic SM, respectively, observed in a 12-week-old ASMD fetus. 18 Before the development of more specific enzymatic and molecular assays, biopsy of various tissues was used to aid in the diagnosis of lysosomal storage diseases. 1 However, ideal fixation and staining of these specimens was not usually achieved, as routine paraffin processing of these tissues results in a nonspecific vacuolated appearance and the loss of the specific substrate deposits. The inclusion of liver and skin biopsies as part of the protocol for a phase 1 trial of recombinant human acid sphingomyelinase (rhASM) in adults with NPD-B provided a unique opportunity to prospectively analyze biopsy tissues. Optimal collection, preservation, processing, and staining of tissues was ensured by applying novel processing and staining techniques that were developed and validated (Taksir et al, unpublished data) in an ASM knock-out mouse model. 2 In this communication we report the findings from a comprehensive histologic characterization of liver and skin biopsy specimens from patients with NPD-B, using standard methods and high-resolution light microscopy (HRLM) for quantification of SM content by computer morphometry, and electron microscopy (EM) to confirm the presence and cellular localization of stored SM. Successful use of biopsy pathology as a biomarker of efficacy has been demonstrated previously in studies on Fabry disease 14, 15, 17 and Pompe disease. 4, 16 In this phase 1 study, we evaluated the biopsy pathology of ASMD in both liver and skin samples, and we assessed their utility as biomarkers of safety and disease burden for the present and future trials.
METHODS

Study Design and Human Subjects
A phase 1 trial of rhASM in adults with NPD-B that included baseline and day 14 liver and skin biopsies was approved by the Mount Sinai School of Medicine Institutional Review Board. All patients gave written informed consent before any study-related procedures. Inclusion criteria for enrollment in the study were: 18 to 65 years of age, confirmed deficiency of ASM enzyme activity, spleen volume Z2 multiples of normal (based on a normal spleen volume of 0.2% of body weight), diffusion capacity for carbon monoxide >30% predicted, serum aspartate aminotransferase and alanine aminotransferase r250 IU/L, bilirubin r3.6 mg/dL, international normalized ratio r1.5, and platelet count Z60,000/mL. Exclusion criteria included histopathologic evidence of cirrhosis and use of agents known to be hepatotoxic, promote bleeding, or inhibit rhASM. All patients tested negative for hepatitis A, B, and C, and none had a history of alcohol abuse.
As histopathologic evidence of cirrhosis on baseline liver biopsy was an exclusion criterion for participation in the trial, 17 adult patients with ASMD ranging in age from 18 to 54 years underwent baseline core biopsies of the liver and 3-mm punch biopsies of the skin during screening. Two patients were excluded because of cirrhosis and a third for the presence of inflammatory foci; 3 others were excluded for other reasons. Eleven eligible patients were assigned to 1 of 5 dose cohorts of a single dose of intravenous rhASM (0.03, 0.1, 0.3, 0.6, and 1.0 mg/kg) and had repeat liver and skin biopsies at day 14 postdose. There were no significant changes postdose except for 1 day 14 liver biopsy with 2 small inflammatory foci, 1 with hepatocyte degeneration, classified as an adverse drug reaction.
Fresh liver samples were divided and placed into 10% neutral buffered formalin and a fresh mixture of 2% glutaraldehyde/2% paraformaldehyde in 0.2 mol/L sodium cacodylate buffer, pH 7.3, for histopathologic analyses. A separate piece was frozen in liquid nitrogen for biochemical analysis of SM. Punch biopsies of skin were preserved in 2% glutaraldehyde/2% paraformaldehyde in 0.2 mol/L sodium cacodylate buffer, pH 7.3. Gross photos of fixed biopsies were taken before processing.
Paraffin Processing of Liver Biopsies for Special Stains and Immunohistochemistry
The liver biopsy specimens that were immersionfixed in 10% neutral buffered formalin were dehydrated in ascending grades of reagent alcohol, cleared in xylenes, infiltrated, and embedded into Paraplast X-TRA paraffin (McCormick Scientific LLC, St Louis, MO) on a Tissue-Tek VIP tissue processor (Sacura Finetek Japan Co., Tokyo, Japan). Sections of 5 mm thickness were cut on a Leica microtome and mounted onto Fisherbrand Superfrost Plus Slides (Fisher Scientific, Pittsburgh, PA). Slides were stained with modified hematoxylin and eosin (H&E), Masson trichrome, and Gordon-Sweets reticulin stains according to standard methods. 10 Immunohistochemical analysis for the macrophage-specific marker, CD68, was performed using a mouse anti-human CD68 antibody (clone PG-M1, catalog# M0876; Dako, Carpinteria, CA) at a concentration of 0.4 mg/mL. Slides were stained with diaminobenzidine (Dako) chromogen solution and a hematoxylin counterstain (Dako).
Tissue Processing for HRLM and EM
One-millimeter cubes of each tissue specimen were fixed for a minimum of 24 hours in 2% glutaraldehyde/ 2% paraformaldehyde in 0.2 mol/L sodium cacodylate buffer, pH 7.3. The tissues were then washed in 0.2 mol/L sodium cacodylate buffer overnight and placed in a working solution of 2.5% potassium dichromate and 0.5% osmium tetroxide in reverse osmosis/deionized water for 6 hours at room temperature, followed by washing in running water for 1 hour. The tissues were then stored overnight in 30% ethanol at 41C, followed by dehydration in acetones (70% and 100% acetones for 30 min each). After dehydration the tissues were infiltrated in 70% resin [15 mL dodecenyl succinic anhydride, 5 mL LX-112, 5 mL Araldite 502, and 0.5 mL DMP-30 (Ladd Research Industries, Williston, VT)] in acetone for 1 hour. The tissues were then infiltrated in 2 changes of 100% resin, 1 at 3 hours and 1 overnight. Embedding was performed in "00" Beem capsule with 100% resin and polymerized at 601C for a minimum of 48 hours. Sections of 1 mm thickness were cut using a Leica EM UC6 microtome (Leica Microsystems) with an ultradiamond knife (Diatome, Hatfield, PA). The sections were collected on Superfrost Plus Slides and dried overnight on a 401C slide warmer.
Modified Toluidine Blue Staining of Epon-Araldite Sections for HRLM
Slides were hydrated in water for 1 minute. The slides were then treated with a filtered solution of 0.5% tannic acid in a Ringer solution buffer, pH 6.8 (Electron Microscopy Sciences, Hatfield, PA), for 15 minutes, followed by rinsing in running water for 5 minutes. Slides were then stained for 2 minutes with a 1% solution of toluidine blue/borax, pH 8.4 (heated to 601C). After staining, sections were washed in running water for 5 minutes and then dried completely in a 601C oven and coverslipped with TBS SHUR/Mount xylene-based mounting medium (Triangle Biomedical Systems Inc., Durham, NC). When performed successfully, the areas containing SM stain purple, nuclei stain dark blue, and cytoplasm and other elements stain light blue. The distinct color contrast thus renders these slides suitable for MetaMorph image analysis.
Lysenin Affinity Staining on Epon-Araldite Sections
Epon sections were hydrated in Tris buffered saline (TBS) (Dako) with 0.1% Tween-20 (TBS-T; Dako) for 5 minutes. For SM staining, a 5 mg/mL solution of lysenin protein (Peptides International, Louisville, KY) was diluted in TBS with 0.5% bovine serum albumin (TBS-B; Dako) and placed on the slides and incubated at 371C for 1 hour. After rinsing in TBS-T, a 1:2500 dilution of rabbit antilysenin antiserum (Peptides International) diluted in TBS-B was added to the slides for 30 minutes at room temperature. After another TBS-T rinse, MACH2 rabbit alkaline phosphatase polymer (Biocare Medical, Concord, CA) was applied for 30 minutes at room temperature. After rinsing in TBS-T, slides were developed in Vulcan Fast Red chromogen (Biocare Medical) and counterstained in a 1:10 dilution of Richardson stain (heated to 601C) for 15 seconds. Once thoroughly rinsed in running tap water, the slides were air dried, mounted with TBS SHUR/Mount xylene-based mounting medium (Triangle Biomedical Systems Inc.) and coverslipped. Using this method, SM appeared red against a light blue background.
Transmission Electron Microscopy
Ultrathin sections of 70 nm thickness were cut from liver and skin epon blocks and mounted on 200-mesh copper grids. The grids were stained with Leica EM Stain (Leica Microsystems) containing 0.5% aqueous uranyl acetate and 3% lead citrate solution. Images were acquired on a JEOL JEM-1400 transmission electron microscope (JEOL, Peabody, MA) using a Gatan 785 Erlangshan ESW1000 digital camera (Gatan Inc., Pleasanton, CA).
MetaMorph Digital Analysis
MetaMorph analysis was performed as described elsewhere. 4 Briefly, 1 representative field from each slide was photographed with a Nikon DXM1200 digital camera and acquired with the Nikon Act 1 photo image capture software for the DXM1200 digital camera, version 1.12 (Nikon Inc., Instrument Group, Melville, NY). Each digital image was photographed with the Â 60 objective and formatted at a fixed pixel density (8Â 10 inches at 150 dpi) using Adobe PhotoShop software (version 5.5). Each digital image was then opened using the MetaMorph Imaging Processing and Analysis software (version 6.3, Universal Imaging Corporation) for histomorphometric analysis.
MetaMorph was used to quantify the amount of SM staining as a percentage of total tissue area in each digital image. The area of total tissue (designated as Image A and represented by purple and blue staining together) and the area occupied by SM (designated as Image B and represented by purple staining only) were calculated in terms of pixels. The colocalization function of MetaMorph then calculated the percentage of pixels in common between Image A and Image B and automatically exported the calculation into an Excel spreadsheet.
Pixel area of sphingomyelin Pixel area of all tissue Â100 % ¼ Percent area of tissue occupied by sphingomyelin: Up to 10 blocks were produced from each patient's liver biopsy (sample size permitting). One section from each block was cut, stained, mounted on a slide, and analyzed as described above. This "breadloaf" approach ensured the evaluation of SM in up to 10 slides representative of the distribution across the entire length of sample. The average and SD were calculated from each set of sections.
Biochemical Analysis of SM
Liver biopsy samples were cut into approximately 1 Â 1 Â 5 mm pieces, flash frozen, and stored at À 801C until processed. Each piece of tissue was subsequently extracted twice with 0.5 mL of chloroform:methanol (2:1) solvent and homogenized for 30 seconds using a sonic homogenizer, and the final 1.0 mL was incubated for 15 minutes at 371C on a rocking platform. The cell debris was removed by centrifugation, and 200 mL of water was added to each sample tube. The samples were vortexed and centrifuged (5 min at 16,100g) to separate the phases. The top aqueous phase was analyzed for total protein concentration using the Bicinchoninic Acid Protein Assay kit following the manufacturer's instructions (Thermo Scientific-Pierce, Rockford, IL). Protein concentrations were interpolated using a bovine serum albumin standard curve (Thermo Scientific-Pierce). The bottom organic phase was used for SM quantification. This organic phase was dried under nitrogen, resuspended, and then cleaned up by liquid-liquid extraction. SM contains a long-chain fatty acid of varying lengths and degrees of saturation. Therefore, SM levels can be reported as a summation of these isoforms (total SM). Each isoform was quantified by mass spectrometry (MS). Multiple reaction monitoring mode MS/MS technique using a structure-specific product ion (m/z 184) from the phosphorylcholine head group from SM isoforms was used to measure total SM concentrations. SM isoforms were separated by liquid chromatography before being subjected to MS/MS analysis. Because of the high SM concentration present, the liver samples were diluted at 1/10, 1/50, and 1/500 and tested for SM at all dilutions to ensure that at least 1 dilution was within the standard curve quantification range. Due to lack of human liver matrix, a methanol standard curve was used in clinical sample testing. Comparability between liver matrix curve and methanol curve was established. The standard curve (signal as ratio of standard/ internal standard vs. SM concentration at 0, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, and 5 mg/mL) used linear curve fit with 1/x weighting. Sample signal was interpolated from the standard curve to generate SM concentration values. SM concentration was normalized to tissue protein concentration [SM (mg)/protein (mg)] determined by bicinchoninic acid assay.
Biochemical Analysis of ASM Activity in Patient Fibroblasts
ASM activity in lysates of cultured dermal fibroblasts from patient skin biopsies was measured using the Amplex Red kit (Molecular Probes, Eugene, OR; catalog# A12220). The assay was performed in 2 steps. First, ASM hydrolyzed the natural substrate (SM) in acetate buffer at pH 5.0 to yield ceramide and phosphorylcholine. In the second step, a Tris solution containing 3 additional enzymes (alkaline phosphatase, choline oxidase, and horseradish peroxidase) and a second substrate (Amplex Red) was added to the reaction mix to terminate the first reaction and produce a fluorescent product (resorufin) from phosphorylcholine. The amount of fluorescence was compared with that produced from known quantities of resorufin in a standard curve. Consequently, the amount of fluorescence was directly proportional to the amount of ASM present in the sample. The normal range for ASM activity in normal adult cultured fibroblasts was determined to be 84.9 to 402.4 nmol/h/mg. The Below Assay Quantitation Limit was defined as <2.7 nmol/h/mg.
Statistical Methods
To assess correlations between variables such as baseline age, degree of splenomegaly, hepatomegaly, SM storage by morphometry, and biochemical measurements of SM, changes and percentages in these variables and rhASM dose, Pearson correlation coefficients, and P-values were computed.
RESULTS
Liver Biopsy Pathology
Formalin-fixed, paraffin-embedded liver biopsies were assessed for fibrosis according to the Laennec scoring system, 7 which grades the extent of fibrosis on a scale from 0 to 4 (0, no fibrosis; 1, minimal; 2, mild; 3, moderate; 4, cirrhosis). Two of the 17 patients (12%) had scores of 0. The remaining 15 patients (88%) had evidence of fibrosis as follows: grade 1, 5 patients (29%); grade 2, 6 patients (35%); grade 3, 2 patients (12%); and grade 4, 2 patients (12%) ( Table 1 ). Since cirrhosis was an exclusion criterion, the latter 2 patients (aged 39 and 40) were excluded from the remainder of the phase 1 trial as per protocol. Figure 1 compares the histopathology of 2 representative liver biopsies with grade 0 (no fibrosis) and grade 4 (cirrhosis), respectively. The biopsy in Figure 1A (patient 6) exhibited relatively undisturbed hepatocellular architecture on reticulin-stained sections and the corresponding trichrome stain demonstrated the absence of fibrosis (Fig. 1C) ; SM-laden Kupffer cells presented as single cells within sinusoids (arrows). Conversely, the cirrhotic biopsy in Figure 1B (patient 16) demonstrated marked distortion of the normal lobular architecture throughout the specimen on reticulin-stained sections. Trichrome-stained sections (Fig. 1D ) showed pericellular fibrosis, which develops around large swaths of Kupffer cells near portal areas.
Liver SM Content
The 17 baseline liver biopsies had variable amounts of SM accumulation. The cell-specific localization of SM varied depending on the total amount of SM staining, and specific distribution patterns were noted. In the 2 patients (patients 4 and 6) with the lowest levels of SM staining, the cellular distribution was largely limited to sinusoidal Kupffer cells (K distribution), which appeared as enlarged foamy cells present in sinusoids on H&E-stained sections ( Fig. 2A; patient 6 ). Of interest, these 2 patients also had the highest levels of residual ASM activity as measured in the fibroblast assay (Table 1 ). In epon-embedded samples, SM was preserved within Kupffer cells and stained purple with the modified toluidene blue (Fig. 2C) and red with the lysenin affinity stain ( Fig. 2E ). Immunohistochemistry staining for the macrophage marker, CD68, highlights the K distribution in Figure 2G .
In the remaining 15 biopsies, higher amounts of SM staining were visible within large swaths of Kupffer cells in portal areas and within hepatocytes across the entire biopsy (KH pattern). H&E-stained sections from these 15 samples demonstrated hepatocytes with a finely vacuolated cytoplasm (lysosomal storage) throughout the specimen along with multiple clusters of foamy Kupffer cells (eg, Fig. 2B, patient 1) . Figures 2D and F illustrate the toluidene blue and lysenin affinity staining of SM in both cell types. In Figure 2H , immunohistochemical staining for CD68 clearly shows the enlarged Kupffer cells present as single cells within the sinusoids, as well as the proliferation of additional SM-laden Kupffer cells, which clustered and infiltrated bands of fibrosis near portal areas.
EM of Liver Biopsies
Lysosomal accumulation of SM was confirmed in hepatocytes ( Fig. 3A ) and in clusters of Kupffer cells by EM (Fig. 3B ). In hepatocytes, lysosomes were enlarged by the SM storage, which appeared as small zebra bodies and loose myelin figures scattered throughout the cytoplasm. In Kupffer cells, lysosomal SM storage appeared as large, tight myelin figures packed side by side and occupying nearly the entire volume of the cell. EM also revealed low levels of SM accumulation in sinusoidal endothelial cells ( Fig. 3C ) and bile duct epithelial cells (Fig. 3D ), which were not visible at the light microscopy level.
MetaMorph Analysis of Hepatic SM Levels, Before and After rhASM Infusion
MetaMorph quantification of SM storage is shown in Figure 4A . At baseline 2.7% to 44.6% of total tissue area was occupied by SM ( Fig. 4B and Table 1) , with a mean of 26.3% ± 13.0%. Note that the biopsies from patients 4 and 6 had the lowest levels of SM accumulation, which was limited to Kupffer cells. In the adjacent liver samples frozen at the time of biopsy, SM levels measured biochemically ranged from 533 to 13,567 mg/mg protein.
The degree of SM storage by morphometry correlated with the biochemical measurement of SM at day 14 postinfusion (r = 0.73; P = 0.02) but not at baseline (r = 0.53; P = 0.18), which may be due to sampling variability, methodology differences, and the small number of samples available for biochemical evaluations (N = 8 to 9). The degree of SM storage by morphometry also correlated with the degree of hepatomegaly (r = 0.59; P = 0.01) and trended with the degree of splenomegaly (r = 0.45; P = 0.07), both of which are clinical indicators of lysosomal storage. The degree of SM storage by morphometry cor-related inversely with the amount of residual ASM activity in fibroblasts (r = À 0.52; P = 0.04) such that lower activity was associated with more SM accumulation. Meta-Morph quantification of SM in baseline and postinfusion biopsies suggested a trend toward SM reduction after a single infusion at higher doses (r = À 0.57; P = 0.07).
Notably, there was no correlation between SM levels and either fibrosis grade or patient age. Like SM (by morphometry), the baseline fibrosis grade also appeared related to spleen volume (r = 0.48; P = 0.05) and ASM activity (r = À 0.49; P = 0.05) but, unlike SM, not to liver volume (r = 0.33; P = 0.19). Splenomegaly and hepatomegaly showed a high correlation (r = 0.80; P < 0.01). It should be noted that, in addition to SM accumulation in splenic macrophages, the portal hypertension reported in NPD patients may also, in part, contribute to splenomegaly. 8, 13 Summary of patient number, age, fibrosis score, residual enzyme levels, MetaMorph measurement for hepatic SM before and after treatment, biochemical measurement of hepatic SM, and baseline liver and spleen sizes (as multiples of normal).
The adult normal fibroblast ASM activity range was defined as 84.9 to 402.4 nmol/h/mg. The below assay quantitation limit was defined as <2.7 nmol/h/mg. NA indicates measurement not performed; NA*, biochemical measurement not available due to protein concentration being out of range for the assay.
Isolated Liver Observations
The appearance of the baseline biopsy from patient 13 (Figs. 5C, D) deviated notably from the typical fine pericellular fibrosis around the foamy Kupffer cell infiltration typically observed in most of our liver biopsies (Figs. 5A, B ). This biopsy contained 2 prominent lymphoid aggregates (Fig. 5C ) in association with distinct foci of dense periportal fibrosis (staining intense blue on trichrome-stained sections, Fig. 5D ) devoid of foamy cell infiltration, although foamy Kupffer cells and finely vacuolated hepatocytes were scattered throughout the rest of the hepatic parenchyma. These dense, fibrotic, inflammatory lesions were not observed in any other baseline biopsy. The patient was noted to have a prior history of prescription medications with known hepatotoxicity. Therefore, these foci may represent an unrelated, preexisting secondary process, such as a chronic drug-induced hepatitis.
The postinfusion biopsy from patient 10 (0.6 mg/kg rhASM) contained a 0.5-mm diameter focus of lymphocytic infiltrate associated with hepatocellular degeneration (Fig. 5E ). The focus of hepatocellular degeneration appeared hyperchromatic on trichrome-stained sections (Fig. 5F) . A second 0.1-mm cluster of lymphocytes was also present but was not associated with hepatocellular degeneration. These inflammatory and degenerative changes were not observed in the patient's baseline biopsy, and consequently, this posttreatment change was reported as a mild adverse drug reaction. 
SM Accumulation in Skin Biopsies
The amount of SM staining in skin was much lower than that in liver. All samples had <1% of the tissue area involved. These low levels of SM were more easily detected with the lysenin affinity staining method, in which the red chromogen provided greater contrast against the blue counterstain (Figs. 6A, B) . SM storage was present in multiple cell types, including dermal fibroblasts, macrophages, vascular endothelial cells, vascular smooth muscle cells, perineurium, and Schwann cells as confirmed by EM ( Figs. 6C-F ). There were no qualitative differences in SM accumulation in postinfusion skin biopsies.
DISCUSSION
This phase 1 study provided a unique opportunity to prospectively characterize the liver and skin histopathology in 17 adult patients with ASMD, with a special emphasis on characterizing the SM accumulation and its cellular distribution. "Niemann-Pick cells," "sea-blue histocytes," "foam cells," and "lipid-laden macrophages" are all terms found in the historical literature to describe the iconic histologic appearance of phagocytic cells in ASMD. Although macrophages of liver, spleen, lung and bone marrow are the earliest and most prominently affected cells, 8, 19 this study has documented SM accumulation in other cell types including hepatocytes, bile duct epithelium, vascular endothelial cells, vascular smooth muscle cells, perineurium, and Schwann cells.
An important new finding is documentation of the presence of variable degrees of fibrosis in nearly all study patients, with progression to cirrhosis in 2 patients who did not have any clinical symptoms of liver failure. Previously, hepatic fibrosis and cirrhosis have only been reported in a small number of severely affected young patients. 3, 20 Single reports of hepatic failure 8 and gastrointestinal bleeding and ascites 13 have also been previously reported. In the general population, cirrhosis is a risk factor for hepatocellular carcinoma, 7 and although hepatocellular carcinoma has occurred in a few NPD case reports 1 (M.M.M., unpublished data), it difficult to determine whether the incidence is higher in NPD patients. Another important finding was the wide variability in the degree of SM accumulation and 2 specific patterns of storage: patients with low levels of SM storage showed staining in isolated Kupffer cells, whereas those with higher levels of SM also showed staining within hepatocytes along with the swaths of Kupffer cells associated with pericellular fibrosis. On the basis of the pathophysiology of the disease, NPD patients with lower amounts of residual ASM activity are expected to store greater amounts of lysosomal SM, resulting in higher SM levels in liver biopsies and larger organ volumes. These relationships were supported by the various correlation determinations. For example, the patient with the lowest liver SM level by MetaMorph analysis (2.7% of tissue area in patient 4) had the least liver enlargement, calculated as 1.04 multiples of normal by magnetic resonance imaging measurement, whereas patients with higher SM levels had more pronounced liver enlargement (r = 0.59; P = 0.01; Table 1 ) and prominent accumulation in hepatocytes. Surprisingly there was no correlation between SM content and fibrosis grade, and less surprisingly, no correlation between liver size and fibrosis grade, which suggest that substrate storage is not the sole determinant of the development of fibrosis in the liver. Indeed, one would expect fibrosis to have the opposite effect on liver volume when compared with SM storage, that is, whereas livers in early cirrhosis may not be shrunken, a fibrotic liver that is progressing toward end-stage cirrhosis should become smaller over time. There was, however, a strong correlation between liver size and spleen size (r = 0.80; P < 0.01) and additional suggestive correlations of spleen size with liver SM storage (r = 0.45; P = 0.07) and fibrosis (r = 0.48; P = 0.05), which lend further support to the use of spleen size as a global indicator of disease severity. 6 As has been seen for other disease manifestations in ASMD, patient age was not a predictor of histologic severity. Indeed the patient with the lowest SM levels was among the oldest in this trial. This finding is consistent with the significant disease heterogeneity among affected patients with ASMD, which is presumed to be due to the severity of the specific underlying genetic mutations in SMPD1 and the amount of residual enzymatic activity. 5, 11, 12 The presence of SM in multiple cell types of the skin suggests that skin biopsy might also serve as a convenient, less invasive biomarker of SM clearance in instances in which liver biopsy is considered too invasive. Skin biopsies have already been utilized successfully as biomarkers of substrate clearance by enzyme replacement therapy (ERT) in Fabry disease. 14 The clearance of globotriaosylceramide (GL-3) from skin biopsies was monitored in parallel with GL-3 clearance from renal 17 and cardiac 15 biopsies in early repeat-dose trials of ERT for Fabry disease. The clearance of GL-3 from the vascular endothelium of the skin paralleled GL-3 clearance from the vascular endothelium of kidney and heart, 2 key target organs of disease in Fabry disease. This demonstrated the utility of skin biopsy as a comparatively noninvasive biomarker in instances in which a treating physician might judge renal and/or cardiac biopsy as too invasive for monitoring purposes.
Although the baseline levels of SM substrate in NPD skin biopsies are less dramatic than SM levels in liver, they are similar to levels of GL-3 substrate observed in Fabry skin biopsies. By assessing SM clearance from skin and liver biopsies in parallel during future repeat-dose studies of ERT for NPD, we hope to determine whether skin biopsy has similar utility in reflecting the efficacy of ERT in other target organs, as was demonstrated in trials for Fabry disease.
In summary, the extensive analysis of liver and skin pathology in a small cohort of ASMD patients reported here demonstrated the common occurrence of liver fibrosis and also served as a postinfusion safety marker. These results also suggest that quantifiable substrate pathology merits further investigation in future repeatdose studies in which such biopsy analyses may serve as useful biomarkers of pharmacodynamic activity during long-term ERT.
